On February 19, 2010
Maybe a Merck Drug Swap With J&J Could Make Its Remicade Headache Go Away
Merck (MRK) could give Claritin and its other consumer brands to Johnson & Johnson (JNJ) in exchange for keeping some of its rights to Remicade, the $2.3 billion inflammatory disease blockbuster that the two companies market jointly.
…
0 Comments